



Identification of a Novel Homozygous Mutation in *BBS10* Gene in an Iranian Family with Bardet-Biedl Syndrome

Mohammad Dehani ¹, Davood Zare-Abdollahi ^{2*}, Ata Bushehri ¹, Azadeh Dehghani ³, Jalil Effati ⁴,
Seyed Ali Mohammad Miratashi ⁵, and Hamid Reza Khorram Khorshid ²

1. Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran

2. Fetal Health Research Center, Hope Generation Foundation, Tehran, Iran

3. Medical Biotechnology Research Center, Ashkezar Branch, Islamic Azad University, Ashkezar, Iran

4. Meybod Genetic Research Center, State Welfare Organization, Yazd, Iran

5. Department of Ophthalmology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

Abstract

Background: Bardet-Biedl Syndrome (BBS) is a rare pleiotropic autosomal recessive disease related to ciliopathies with approximately 25 causative genes. BBS is a multi-systemic disorder with wide spectrum of manifestations including truncal obesity, retinal dystrophy, male hypogenitalism, postaxial polydactyly, learning difficulties, and renal abnormalities.

Methods: A consanguineous Iranian family with a 28-year-old daughter affected with BBS, resulting from a first cousin marriage, was examined. After clinical examination, Whole Exome Sequencing (WES) was applied. Following the analysis of exome data, Sanger sequencing was used to confirm as well as to co-segregate the candidate variant with the phenotype.

Results: A novel homozygous variant [c. 2035G>A (p.E679K)] in exon 2 of the *BBS10* gene was found which was categorized as likely pathogenic based on American College of Medical Genetics and Genomics (ACMG) guidelines and criteria. In this study, the variant was fully co-segregated with the phenotype in the family.

Conclusion: Despite overlapping with other ciliopathies in terms of the phenotype, the BBS has high genetic heterogeneity and clinical variability even among affected members of a family. The symptoms observed in patients are largely related to the genes involved and the type of mutations in the BBS. In this study, in addition to phenotype description of the proband harboring a novel disease-causing variant in *BBS10* gene, the spectrum of BBS symptoms was expanded. The findings of this study can be useful in genetic counseling, especially for risk estimation and prenatal diagnosis.

Avicenna J Med Biotech 2021; 13(4): 230-233

Keywords: Bardet-Biedl syndrome, Mutation, Whole exome sequencing

Introduction

Bardet-Biedl Syndrome (BBS; OMIM# 209900) is a rare pleiotropic autosomal recessive disease characterized by learning difficulties, male hypogenitalism, renal abnormalities, retinal dystrophy, obesity, and postaxial polydactyly ¹. Secondary features may include metabolic and cardiovascular defects, hearing loss, ataxia, anosmia, diabetes, speech deficits, strabismus, hypertension, and dental malformations ^{2,3}. At present, approximately 25 causative genes have been identified that can explain molecular causes in about 80% of affected families ⁴⁻⁶. Among these BBS-associated genes, the most involved genes are *BBS1* (23.2%), *BBS10* (20%), *BBS2* (8.1%), *BBS9* (6%), *MKKS*

(5.8%), *BBS12* (5%), and *MKS1* (4.5%) ⁷⁻¹⁰. BBS is a rare disorder with a prevalence of about 1 in 150000 individuals worldwide ¹¹. The criteria needed to clinically confirm the disorder upon examination include three or four main in addition to at least two minor symptoms of the BBS ^{12,13}. In most patients, the inheritance pattern of BBS is autosomal recessive but nearly 10% of the BBS subjects have digenic triallelic inheritance ¹⁴. BBS belongs to a class of ciliopathies that are the biogenesis and the function of cilia ¹⁵. *BBS10* gene has two exons and a length of 23.97 Kb ². *BBS10* protein consists of 723 amino acids and has three functional domains: equatorial, intermediate, and apical ³.

* Corresponding author:

Davood Zare-Abdollahi, Ph.D.,
Fetal Health Research Center,
Hope Generation Foundation,
Tehran, Iran

Tel: +98 9138502360

Fax: +98 21 22180138

E-mail:

davood.zareabdollahi@gmail.
com

Received: 1 Mar 2021

Accepted: 3 May 2021

The purpose of this study was to report a 28-year-old woman with BBS with a novel homozygous mutation [c.2035G>A (p.E679K)] in the second exon of *BBS10* gene.

Materials and Methods

Patients

A consanguineous Iranian family with symptoms of BBS disease was enrolled in this study. The family was from Yazd province and had only one affected 28-year-old daughter and 5 unaffected children (Figure 1). Clinical examinations were carried out by a clinical geneticist that verified three main features of learning problems, retinal dystrophy (Retinitis pigmentosa), and obesity in the patient (Figure 2A and 2B). Moreover, there were other manifestations in the patient such as hypothyroidism, hypertension, seizure, developmental delay, mild ID, and lingual problem. Additionally, for confirmation of the retinitis pigmentosa phenotype, ophthalmic examinations were performed including Optical Coherence Tomography (OCT) and fundus photography (Figure 2C-E). Informed consent was obtained from the patient and her family. This study was consistent with the Helsinki Declaration and methods accepted by the Research Ethics Committee (REC) (Approval number 1396.333) of University of Social Welfare and Rehabilitation Sciences (USWR) ¹⁶.

Mutation analysis

At first, 6 ml of blood sample from peripheral blood lymphocytes was taken from the patient, her parents, and other participants of the family and then genomic DNA was extracted by salting out method. Quality of the extracted DNA was examined by NanoDrop machine. Next, the sample was sent for Whole Exome Sequencing (WES), based on Next Generation Sequencing (NGS), to determine the sequence. Agilent SureSelect Human All Exon V6 (Agilent Technologies Inc., USA) was employed for exon enrichment. For se-




Figure 2. Clinical symptoms of BBS proband. Funduscopy (A) and OCT (B and C) of both right and the left eyes of the affected case. Clinical features of proband (D and E) without polydactyly (F).

quencing reads, Illumina HiSeq 4000 platform (Seoul, Korea) was used at mean depth of coverage of 80X. The Burrows-Wheeler Aligner was applied for aligning the sequence reads with GRCh38 reference genome (<https://www.ncbi.nlm.nih.gov/grc/human> data). Furthermore, the processing of variant calls was completed by the Genomic Analysis Tool Kit (GATK). In data analysis, mutations based on exonic, exonic splice, splicing, frameshift, nonsynonymous, stop gain and stop loss variants with a nucleotide conservation score of GERP++>+2 and CADD>20 were selected and then according to the inheritance pattern compatible with autosomal recessive mode, the heterozygous variants were removed ¹⁷. In the next step, variants with a frequency of more than 0.005% were excluded based on the databases including HEX (<https://www.alzforum.org/exomes/hex>), EVS (<http://evs.gs.washington.edu/EVS/>), 1000 genomes (<http://www.internationalgenome.org/>), gnomAD (<http://gnomad.broadinstitute.org/>), ExAC (<http://exac.broadinstitute.org/>), and Iranian national genome database (Iranome; <http://iranome.ir/>). After filtering the variants, a novel homozygous muta-




Figure 1. Pedigree and sequencing data of the family. A) This pedigree displays a BBS patient from a consanguineous marriage who is the only one affected in her family, B) As shown in chromatograms, proband was homozygous for c.2035G>A mutation and inherited mutation from both carrier parents. Also, two normal brothers (RP055 and RP056) who participated in this study were carriers of mutation.

tion (c.2035G>A (p.E679K)) was found in exon 2 of the *BBS10* gene. This variation is considered as a likely pathogenic mutation based on the American College of Medical Genetics and Genomics (ACMG) guidelines and criteria¹⁸. The pathogenicity of c.2035G>A mutation was examined by some *in silico* tools like SIFT¹⁹, polyphen-2²⁰ and Mutation Taster²¹. For confirmation of the segregation and candidate mutation in all the family members, Primer3 (<http://frodo.wi.mit.edu/primer3/>) was applied to design the primer set for second exon of *BBS10* gene including forward primer 5'-GCTGGTTGTGTTTTGCCAGT-3', and reverse primer 5'-ATGAAGGAGGGCTGGAGTGA. After amplification of *BBS10* gene using the polymerase chain reaction, Sanger sequencing was applied in order to sequence the amplicons using ABI BigDye terminator and ABI 3730×1 DNA Analyzer (Applied Biosystems, USA). In this study, CodonCode Aligner 8.0.2 was used to analyze the sequencing results.

Results

As mentioned, one BBS patient from a consanguineous marriage was examined. WES was performed on the patient and data analysis led to the identification of a novel putative homozygous mutation [c.2035G>A (p.E679K)] in *BBS10* gene. This mutation based on ACMG guidelines is considered as a likely pathogenic mutation. Also, further analysis by various *in silico* tools demonstrated that this change could be considered as a result of a disease-causing variant. Furthermore, the CADD and GERP ++ scores indicate the high conservation of this locus during evolution. Therefore, missense mutation at this locus could potentially have a detrimental effect on protein function and eventually lead to pathogenicity (Table 1). Then, PCR products sequenced by Sanger sequencing confirmed the presence of this mutation. Additionally, segregation analysis revealed that both parents were heterozygous for the mutation transmitted from them to the patient, which is indicated in figure 1B.

Discussion

BBS is a rare genetic disorder with 25 genes identified in this disease^{5,6}. In this study, c.2035G>A mutation was detected in the *BBS10* gene. Notwithstanding

the fact that variable mutations occur in *BBS10*, the most common mutation in this gene is p.C91LfsX5¹². *BBS1* and *BBS10* genes have a high incidence of mutation worldwide whereas the studies conducted in Iran showed that *BBS4* and *BBS7* genes have the greatest role in occurrence of the disease in Iranian population⁷. Clinical examinations on the patient revealed that she had three out of the six main symptoms, along with several other secondary symptoms. Among the primary features, the patient had truncal obesity, learning difficulties, and retinal dystrophy. Although the sign of postaxial polydactyly is found in most BBS patients, our patient did not exhibit the symptom (Figure 2F)²². The detailed ophthalmologic examination, along with OCT and fundus photography indicated that the vision problem was actually retinitis pigmentosa, followed by night blindness, visual field defect, progressive photophobia, photopsia, color vision defect, and impaired visual acuity. The patient exhibited secondary complications including hypertension, developmental delay, and lingual problem. Additionally, in our patient, few other symptoms were displayed such as tonic-clonic seizure as well as hypothyroidism, which have not been mentioned in the literature, suggesting that c.2035G>A mutation in the *BBS10* gene could lead to such symptoms.

Conclusion

In our study, after identification of a novel homozygous variant c.2035G>A in *BBS10* gene, two phenotypes of seizure and hypothyroidism were found that were not reported in previous studies. Due to scarcity of data and also high genetic and clinical heterogeneity of this disease, these two phenotypes can be regarded as symptoms of BBS. Given that few studies have been carried out so far on BBS patients in Iran, further studies should be implemented to confirm the above findings and understand different aspects of the disease besides its symptoms in Iranian community in order to improve prenatal diagnosis and apply the findings in genetic counseling.

Acknowledgement

We would like to acknowledge the participation of the daughter, her family, and the colleagues who

Table 1. *In silico* analysis of c.2035G>A (p.E679K) mutation in *BBS10* gene

Gene	Exon	Nucleotide change	Protein effect	Type of mutation	MAF ^a			SIFT	Mutation taster	Polyphen-2	CADD	GERP++	ACMG classification
					GnomAD	Exac	1000G						
<i>BBS10</i>													
RefSeq													
OMIM# 610148	2	c.2035G>A	p.E679K	Mis-sense	N/A ^b	N/A	N/A	Damaging	Disease causing	Probably damaging	29.6	4.91	Likely pathogenic
NM_024685.4													

MAF: Minor allele frequency; N/A: Not available

helped us in this study.

References

1. M'hamdi O, Redin C, Stoetzel C, Ouertani I, Chaabouni M, Maazoul F, et al. Clinical and genetic characterization of Bardet–Biedl syndrome in Tunisia: defining a strategy for molecular diagnosis. *Clin Genet* 2014;85(2):172-7.
2. Khan S, Ullah I, Touseef M, Basit S, Khan MN, Ahmad W. Novel homozygous mutations in the genes ARL6 and BBS10 underlying Bardet–Biedl syndrome. *Gene* 2013; 515(1):84-8.
3. Kurata K, Hosono K, Hikoya A, Kato A, Saitsu H, Minoshima S, et al. Clinical characteristics of a Japanese patient with Bardet–Biedl syndrome caused by BBS10 mutations. *Jpn J Ophthalmol* 2018;62(4):458-66.
4. Forsythe E, Sparks K, Best S, Borrowes S, Hoskins B, Sabir A, et al. Risk factors for severe renal disease in bardet–biedl syndrome. *J Am Soc Nephrol* 2017;28(3): 963-70.
5. base Rd. <https://sph.uth.edu/retnet/notes.htm>. 2019.
6. Niederlova V, Modrak M, Tsyklauri O, Huranova M, Stepanek O. Meta-analysis of genotype-phenotype associations in Bardet–Biedl syndrome uncovers differences among causative genes. *Hum Mutat* 2019;40(11): 2068-87.
7. Fattahi Z, Rostami P, Najmabadi A, Mohseni M, Kahrizi K, Akbari MR, et al. Mutation profile of BBS genes in Iranian patients with Bardet–Biedl syndrome: genetic characterization and report of nine novel mutations in five BBS genes. *J Hum Genet.* 2014;59(7):368.
8. Katsanis N. The oligogenic properties of Bardet–Biedl syndrome. *Hum Mol Genet* 2004;13(suppl_1):R65-R71.
9. Nishimura DY, Swiderski RE, Searby CC, Berg EM, Ferguson AL, Hennekam R, et al. Comparative genomics and gene expression analysis identifies BBS9, a new Bardet–Biedl syndrome gene. *Am J Hum Genet* 2005;77 (6):1021-33.
10. Stoetzel C, Muller J, Laurier V, Davis EE, Zaghoul NA, Vicaire S, et al. Identification of a novel BBS gene (BBS12) highlights the major role of a vertebrate-specific branch of chaperonin-related proteins in Bardet–Biedl syndrome. *Am J Hum Genet* 2007;80(1):1-11.
11. Chandrasekar SP, Namboothiri S, Sen P, Sarangapani S. Screening for mutation hotspots in Bardet–Biedl syndrome patients from India. *Indian J Med Res* 2018; 147 (2):177-82.
12. Billingsley G, Bin J, Fieggen KJ, Duncan JL, Gerth C, Ogata K, et al. Mutations in chaperonin-like BBS genes are a major contributor to disease development in a multiethnic Bardet–Biedl syndrome patient population. *J Med Genet* 2010;47(7):453-63.
13. Chakrabarty S, Savantre SB, Bhat CR, Satyamoorthy K. Multiple genetic mutations implicate spectrum of phenotypes in Bardet–Biedl syndrome. *Gene* 2020;725:144164.
14. Forsythe E, Beales PL. Bardet–Biedl syndrome. *Eur J Hum Genet* 2013;21(1):8-13.
15. Ullah A, Umair M, Yousaf M, Khan SA, Nazim-Ud-Din M, Shah K, et al. Sequence variants in four genes underlying Bardet–Biedl syndrome in consanguineous families. *Mol Vis* 2017;23:482-9.
16. World Medical Association. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. *Bull World Health Organ* 2001;79(4):373-4.
17. Gargis AS, Kalman L, Bick DP, Da Silva C, Dimmock DP, Funke BH, et al. Good laboratory practice for clinical next-generation sequencing informatics pipelines. *Nat Biotechnol* 2015;33(7):689-93.
18. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015;17(5):405-24.
19. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat Protoc* 2009;4(7):1073-81.
20. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. *Nat Methods* 2010;7(4):248-9.
21. Schwarz JM, Rödelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. *Nat Methods* 2010;7(8):575-6.
22. Solmaz AE, Onay H, Atik T, Aykut A, Gunes MC, Yuregir OO, et al. Targeted multi-gene panel testing for the diagnosis of Bardet Biedl syndrome: identification of nine novel mutations across BBS1, BBS2, BBS4, BBS7, BBS9, BBS10 genes. *Eur J Med Genet* 2015;58(12):689-94.